Supplementary prognostic variables for pleural mesothelioma: A report from the IASLC staging committee

63Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

INTRODUCTION:: The staging system for malignant pleural mesothelioma is controversial. To revise this system, the International Association for the Study of Lung Cancer Staging Committee developed an international database. This report analyzes prognostic variables in a surgical population, which are supplementary to previously published CORE variables (stage, histology, sex, age, and type of procedure). METHODS:: Supplementary prognostic variables were studied in three scenarios: (1) all data available, that is, patient pathologically staged and other CORE variables available (2) only clinical staging available along with CORE variables, and (3) only age, sex, histology, and laboratory parameters are known. Survival was analyzed by Kaplan-Meier, prognostic factors by log rank and stepwise Cox regression modeling after elimination of nonsignificant variables. p value less than 0.05 was significant. RESULTS:: A total of 2141 patients with best tumor, node, metastasis (TNM) stages (pathologic with/without clinical staging) had nonmissing age, sex, histology, and type of surgical procedure. Three prognostic models were defined. Scenario A (all parameters): best pathologic stage, histology, sex, age, type of surgery, adjuvant treatment, white blood cell count (WBC) (=15.5 or not), and platelets (=400 k or not) (n = 550). Scenario B (no surgical staging): clinical stage, histology, sex, age, type of surgery, adjuvant treatment, WBC, hemoglobin (<14.6 or not), and platelets (n = 627). Scenario C (limited data): histology, sex, age, WBC, hemoglobin, and platelets (n = 906). CONCLUSION:: Refinement of these models could define not only the appropriate patient preoperatively for best outcomes after cytoreductive surgery but also stratify surgically treated patients after clinical and pathologic staging who do or do not receive adjuvant therapy. Copyright © 2014 by the International Association for the Study of Lung Cancer.

Cite

CITATION STYLE

APA

Pass, H. I., Giroux, D., Kennedy, C., Ruffini, E., Cangir, A. K., Rice, D., … Rusch, V. W. (2014). Supplementary prognostic variables for pleural mesothelioma: A report from the IASLC staging committee. Journal of Thoracic Oncology, 9(6), 856–864. https://doi.org/10.1097/JTO.0000000000000181

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free